Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

-altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown.

fusion-positive thyroid cancer, in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response), as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety.